超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Regulus Therapeutics  
Regulus公司始建于2007年是由Alnylam與Isis兩家制藥公司聯合創建的。 心血管/代謝性疾病項目中擬用于治療動脈粥樣硬化的靶位microRNA-33。

Regulus is focused on the discovery
and development of microRNA therapeutics.

microRNAs are members of a large class of non-coding RNAs of approximately 22 nucleotides in length that regulate most genes in the genome. A single microRNA can target and regulate up to hundreds of genes, and these genes are involved in biological networks or pathways. Dysregulated microRNA expression is involved in the initiation of many complex multi-factoral diseases, including cancer, inflammatory disease, fibrosis, and metabolic disease. microRNA therapeutics are oligonucleotide medicines that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat human disease.

Regulus was formed in September 2007 by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS). Regulus benefits substantially from the collective therapeutic RNA expertise of its founding companies, including established proprietary oligonucleotide-based technologies, and broad and dominant intellectual property estates specific to chemically modified oligonucleotides. Regulus has exclusive rights to over 900 patents and patent applications pertaining to oligonucleotide modifications, conjugates, and design patterns, all for use in targeting microRNA for therapeutic applications. Additionally, in the field of microRNA therapeutics, Regulus exclusively controls over 100 patents and patent applications directed to microRNA specific technologies, including microRNA target sequences, therapeutic uses, drug products, drug designs, and analytical methods.

Regulus is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and drug development. Regulus’ scientific advisory board consists of world-class scientists and several of the foremost authorities in the field of microRNA research.